Amgen secured exclusive global rights to develop and commercialize cancer therapies under a license from DISCO Pharmaceuticals, with DISCO eligible for up to $618 million in deal value. The deal taps DISCO’s surfaceome mapping to guide bispecific ADC and T-cell engager programs for lung and colorectal cancer.